China’s Everest Medicines signed a $121 million pact for Greater China rights to Nefecon, the lead drug of Sweden’s Calliditas Therapeutics. Nefecon is a novel oral formulation of the corticosteroid budesonide aimed at treating chronic autoimmune kidney disease IgA Nephropathy (IgAN). In Sweden, Calliditas has completed a successful Phase IIb trial of Nefecon as a treatment for inflammatory kidney disease in patients at risk of progressing to renal failure. Everest will pay $15 million upfront and the rest in milestones.
Source: China Biotoday
